- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01199133
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis in Adolescents and Children
A Randomised,Double-blind,Placebo-controlled,Multi National,Phase III Trial to Assess the Efficacy and Safety of 300 IR Sublingual Immunotherapy Administered as Allergen-based Tablets Once Daily to Adolescents and Children Above the Age of 5 Years, Suffering From House Dust Mite Allergic Rhinitis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
After the screening period, the patients will be administered 300 IR house dust mite allergen based tablets or placebo, once a day, for a period of 36 months with two windows of 8 months and 6 months without treatment. The carry over effect will be evaluated after a treatment free follow up period of 24 months.
An independent Data Monitoring Committee will be constituted to evaluate the efficacy and safety data at the end of Year 1 and Year 3, and the post-treatment long-term efficacy data at the end of year 4.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female outpatients, aged 5-17 years inclusive
- History of house dust mite-related allergic rhinitis for at least 1 year requiring regular intake of symptomatic treatment(s)
- Sensitised to D. pteronyssinus and/or D. farinae (positive skin prick test with wheal diameter greater than 3 mm and specific IgE level ≥ 0.7 kU/L)
Exclusion Criteria:
• Co-sensitization associated with clinically relevant allergic rhinitis, sinusitis, conjunctivitis or asthma likely to significantly change the symptoms of the patient throughout the study (that means patient symptomatic to another allergen than house dust mites to which the patient will be exposed during the study, i.e. will notably be excluded
- patients sensitised to cat or dog allergens and regularly exposed to these allergens
- patients sensitised to aspergillus, cladosporium, alternaria
- patients sensitised to parietaria , ragweed, or mugwort, if this allergen is endemic to the region
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dpte and Dfar Allergen Extract
|
300 IR, once a day, for one year.
Other Names:
|
Placebo Comparator: Placebo tablets
|
once a day, for one year.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Assessment
Time Frame: 12 months
|
Evaluation of the Average Adjusted Symptom Score (AASS) during the treatment period
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy Assessment at the end of the treatment phase and at the end of the Treatment free follow up phase
Time Frame: 60 months
|
AASS, ARTSS (average rhinitis total symptom score), ARMS (average rescue medication score),ARSS (individual average rhinoconjunctivitis symptom score), RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire Score), Safety
|
60 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ulrich Wahn, MD, Charite- Campus Virchow klinikum
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VO64.08
- 2009-011999-30 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinitis Due to Dust Mite
-
ALK-Abelló A/SActive, not recruitingAllergic Rhinitis Due to Dermatophagoides Farinae | Allergic Rhinitis Due to Dermatophagoides Pteronyssinus | Allergic Rhinitis Due to House Dust MiteSpain, Russian Federation, United States, Poland, Bulgaria, Canada, France, Germany, Lithuania, Slovakia, Ukraine
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusPoland, United Kingdom, Spain, United States, Russian Federation, Hungary, France, Bulgaria, Germany
-
ALK-Abelló A/SITEC ServicesCompletedAllergic Rhinitis Due to House Dust Mite | Allergic Asthma Due to Dermatophagoides Farinae | Allergic Asthma Due to Dermatophagoides PteronyssinusFrance
-
ALK-Abelló A/SCompletedAllergic Rhinitis Due to Dust MiteSpain
-
Eye & ENT Hospital of Fudan UniversityNot yet recruitingAllergic Rhinitis Due to House Dust Mite
-
Gadjah Mada UniversityEnrolling by invitationAllergic Rhinitis | Allergic Rhinitis Due to House Dust MiteIndonesia
-
Inmunotek S.L.LAT Research; Xolomon Tree S.L.Not yet recruitingAllergic Rhinitis | Allergic Asthma | Allergic Rhinoconjunctivitis | Allergy to House Dust MiteArgentina
-
ALK-Abelló A/SEnrolling by invitationAllergic Asthma | Allergic Rhinitis Due to House Dust MiteChina
-
Inmunotek S.L.BioClever 2005 S.L.; NTS hub S.LTerminatedEfficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/RhinoconjunctivitisPerennial Allergic Rhinitis | Allergic Rhinoconjunctivitis | House Dust Mite Allergy | Pollen AllergySpain
-
JOSALYN CHOMassachusetts General HospitalActive, not recruitingAllergic Rhinitis | Allergic Conjunctivitis | Allergic Asthma | Allergy to Cats | Allergy to Dust MitesUnited States
Clinical Trials on Dpte and Dfar Allergen Extracts
-
University of ZurichTerminated
-
Mahidol UniversityCompletedAllergy to Arthropod StingThailand
-
Stallergenes GreerSyneos HealthCompletedSafety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in AdolescentsHouse Dust Mite Allergic RhinitisCanada
-
Albert Einstein College of MedicineJacobi Medical CenterCompleted
-
Stallergenes GreerCompletedAsthma | House Dust Mite AllergyFrance, Germany, Poland
-
Haukeland University HospitalCompleted
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...Completed
-
Inmunotek S.L.CompletedImmune System DiseasesSpain
-
Stallergenes GreerCompletedAsthma | House Dust Mite AllergyFrance
-
Gachon University Gil Medical CenterThermo Fisher Scientific, IncTerminatedAllergic RhinitisKorea, Republic of